Generic Medicine Info
May be taken with or without food.
Biliary cirrhosis, cholestasis. Concomitant use with aliskiren in patient with diabetes mellitus or renal impairment (GFR<60 mL/min/1.73 m2). Severe hepatic impairment. Pregnancy.
Special Precautions
Patients with aortic or mitral stenosis, severe CHF, hypertrophic obstructive cardiomyopathy, post MI, heart failure, ascites due to cirrhosis, refractory ascites, unstented unilateral or bilateral renal artery stenosis, Na- and/or volume-, primary hyperaldosteronism, diabetes mellitus, idiopathic or hereditary angioedema. Patients undergoing major surgery or during anaesthesia. Renal and mild to moderate hepatic impairment. Children. Lactation. Patient Counselling This drug may cause dizziness or weariness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure, electrolytes levels e.g. serum K levels, urinalysis and renal function prior to treatment initiation, during therapy, and periodically thereafter. Assess for signs of angioedema.
Adverse Reactions
Significant: Hypotension, hyperkalaemia, orthostatic hypotension. Rarely, hepatitis. Blood and lymphatic system disorders: Neutropenia, thrombocytopenia. Cardiac disorders: Dyspnoea, palpitation. Gastrointestinal disorders: Diarrhoea, abdominal pain, nausea, dyspepsia, flatulence. General disorders and administration site conditions: Fatigue, asthenia. Infections and infestations: Viral infection. Musculoskeletal and connective tissue disorders: Back pain, myalgia, arthralgia. Nervous system disorders: Dizziness, headache, vertigo, postural dizziness, paraesthesia. Psychiatric disorders: Insomnia, anxiety. Reproductive system and breast disorders: Impotence. Respiratory, thoracic and mediastinal disorders: Cough. Skin and subcutaneous tissue disorders: Rash, pruritus. Vascular disorders: Syncope, vasculitis.
Potentially Fatal: Renal function deterioration characterised by oliguria, progressive azotaemia, and acute renal failure; hepatic injury, cardiac failure. Rarely, angioedema.
Drug Interactions
Increased risk of hyperkalaemia with K-sparing diuretics (e.g. spironolactone, triamterene, amiloride), K supplements or K-containing salt substitutes (e.g. heparin. May increase serum lithium concentration and toxicity. May antagonise hypotensive effect and deteriorate renal function with aspirin, NSAIDs including selective COX-2 inhibitors. Increased systemic exposure with rifampicin, ciclosporin, and ritonavir.
ATC Classification
C09CA03 - valsartan ; Belongs to the class of angiotensin II antagonists. Used in the treatment of cardiovascular disease.
Disclaimer: This information is independently developed by CIMS based on valsartan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in